The estimated Net Worth of Bryan T Baldasare is at least $2.96 Million dollars as of 8 February 2021. Mr. Baldasare owns over 6,254 units of Meridian Bioscience stock worth over $1,906,668 and over the last 5 years he sold VIVO stock worth over $566,813. In addition, he makes $490,759 as Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller und Treasurer at Meridian Bioscience.
Sign up
Mr. Baldasare VIVO stock SEC Form 4 insiders trading
Bryan has made over 4 trades of the Meridian Bioscience stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 6,254 units of VIVO stock worth $187,620 on 8 February 2021.
The largest trade he's ever made was selling 14,250 units of Meridian Bioscience stock on 5 February 2021 worth over $379,193. On average, Bryan trades about 1,500 units every 21 days since 2019. As of 8 February 2021 he still owns at least 56,128 units of Meridian Bioscience stock.
You can see the complete history of Mr. Baldasare stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Bryan Baldasare biography
Bryan T. Baldasare serves as Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller, Treasurer of the Company. Prior to that, Mr. Baldasare served the Company as its Senior Vice President, Corporate Controller and Treasurer. Mr. Baldasare has been employed by the Company since 2000, holding positions of increasing responsibility in the Company’s accounting and finance departments.
What is the salary of Bryan Baldasare?
As the Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller und Treasurer of Meridian Bioscience, the total compensation of Bryan Baldasare at Meridian Bioscience is $490,759. There are 5 executives at Meridian Bioscience getting paid more, with John P. Kenny having the highest compensation of $1,508,705.
How old is Bryan Baldasare?
Bryan Baldasare is 53, he's been the Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller und Treasurer of Meridian Bioscience since 2019. There are 11 older and 1 younger executives at Meridian Bioscience. The oldest executive at Meridian Bioscience Inc. is David Phillips, 81, who is the Independent Chairman of the Board.
What's Bryan Baldasare's mailing address?
Bryan's mailing address filed with the SEC is C/O INMED PHARMACEUTICALS INC., 310-815 WEST HASTINGS ST., VANCOUVER, A1, V6C1B4.
Insiders trading at Meridian Bioscience
Over the last 22 years, insiders at Meridian Bioscience have traded over $8,089,514 worth of Meridian Bioscience stock and bought 228,244 units worth $3,053,655 . The most active insiders traders include Richard Eberly, John P. Kenny und John A Kraeutler. On average, Meridian Bioscience executives and independent directors trade stock every 41 days with the average trade being worth of $424,761. The most recent stock trade was executed by James M. Anderson on 6 January 2023, trading 8,500 units of VIVO stock currently worth $173,230.
What does Meridian Bioscience do?
Meridian Bioscience Inc. is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.The company is dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, Meridian provides critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, Meridian provides diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. The company builds relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.
What does Meridian Bioscience's logo look like?
Complete history of Mr. Baldasare stock trades at Meridian Bioscience und InMed Pharmaceuticals
Meridian Bioscience executives and stock owners
Meridian Bioscience executives and other stock owners filed with the SEC include:
-
John P. Kenny,
Pres, CEO & Director -
John Kenny,
Chief Executive Officer, Director -
Lourdes Weltzien,
Executive Vice President - Life Science -
Dr. Lourdes G. Weltzien Ph.D.,
Exec. VP of Life Science Bus. Unit -
Tony Serafini-Lamanna,
Exec. VP of Diagnostics -
Bryan Baldasare,
Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Corporate Controller, Treasurer -
David Phillips,
Independent Chairman of the Board -
James Anderson,
Independent Director -
Dwight Ellingwood,
Independent Director -
Felicia Williams,
Independent Director -
Catherine Sazdanoff,
Independent Director -
John Rice,
Independent Director -
John McIlwraith,
Independent Director -
Anthony Bihl,
Independent Director -
Melissa A. Lueke,
Consultant -
Susan D. Rolih,
Consultant -
Melissa J. McCarey,
VP of Global HR -
Charles Wood,
VP of Investor Relations -
Jeff Pinkston,
Director of Corp. Fin. -
Julie Smith,
Sr. VP, Controller & Principal Accounting Officer -
Michael C. Shaughnessy,
EVP, Pres Meridian Global Dx -
Amy Winslow,
EVP, Pres & CEO of Magellan -
Melissa Lueke,
Exec VP, CFO -
Marco G. Calzavara,
Pres & Managing Director, MBE -
Vecheslav A Elagin,
Sr VP, Research & Development -
Eric S. Rasmussen,
EVP, Bus. Development/Strategy -
Kenneth Kozak,
Vice President -
Susan Rolih,
EVP, Reg & Quality Systems -
Lawrence Baldini,
VP, Operations -
Robert J Ready,
Director -
Marviette D. Johnson,
VP, Human Resources -
Todd W Motto,
VP, Sales and Marketing -
Grady Barnes,
VP, Research & Development -
Gregory S Ballish,
VP, Sales and Marketing -
James Buzard,
Director -
Richard Eberly,
Ex. VP, Gen Mgr. Mer. Life Sci -
Gary P Kreider,
Director -
Vivo Family Limited Partner...,
10% owner -
William J Motto,
Chairman, CEO -
Antonio Interno,
Senior Vice President -
John A Kraeutler,
Chairman and CEO -
Tony Serafini Lamanna,
Executive VP-Diagnostics